Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Gains from Sales and Divestitures: 2019-2021

  • Silence Therapeutics' Gains from Sales and Divestitures was N/A to $96,443 in Q2 2021 from the same period last year, while for Jun 2021 it was $96,443, marking a year-over-year change of. This contributed to the annual value of -$3,852 for FY2020, which is 250.86% down from last year.
  • According to the latest figures from Q2 2021, Silence Therapeutics' Gains from Sales and Divestitures is $96,443, which was up 2,534.60% from -$3,961 recorded in Q4 2020.
  • In the past 5 years, Silence Therapeutics' Gains from Sales and Divestitures registered a high of $96,443 during Q2 2021, and its lowest value of -$3,961 during Q4 2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1,929 (2019), whereas its average is $24,085.
  • Data for Silence Therapeutics' Gains from Sales and Divestitures shows a maximum YoY plummeted of 254.05% (in 2020) over the last 5 years.
  • Quarterly analysis of 3 years shows Silence Therapeutics' Gains from Sales and Divestitures stood at $2,571 in 2019, then slumped by 254.05% to -$3,961 in 2020, then reached $96,443 in 2021.
  • Its Gains from Sales and Divestitures stands at $96,443 for Q2 2021, versus -$3,961 for Q4 2020 and $2,571 for Q4 2019.